Teva Loses Patent Challenge For Glaxo's Zofran
A federal judge has upheld the validity of two key method-of-use patents for GlaxoSmithKline's anti-nausea drug Zofran (ondansetron), dealing a blow to challenger Teva Pharmaceuticals....To view the full article, register now.
Already a subscriber? Click here to view full article